These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9952382)

  • 1. Codon 215 mutations in human immunodeficiency virus-infected pregnant women. Swiss Collaborative 'HIV and Pregnancy' Study.
    Kully C; Yerly S; Erb P; Kind C; Krautheim A; Perrin L; Rudin C
    J Infect Dis; 1999 Mar; 179(3):705-8. PubMed ID: 9952382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of the T215Y mutation in human immunodeficiency virus type 1-infected pregnant women in a New York cohort, 1995--1999.
    Sitnitskaya Y; Rochford G; Rigaud M; Essajee S; Pollack H; Krasinski K; Borkowsky W
    Clin Infect Dis; 2001 Jul; 33(1):e3-7. PubMed ID: 11389511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of primary resistance to zidovudine and lamivudine in drug-naive human immunodeficiency virus type-1 infected patients: high proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus.
    Trabaud MA; Leriche-Guerin K; Regis C; Bordes I; Cotte L; Detmer J; Kolberg J; Ritter J; Trépo C
    J Med Virol; 2000 Jul; 61(3):352-9. PubMed ID: 10861645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genotypic resistance tests for the management of the HIV-infected pregnant woman.
    Bassetti D; Cargnel A
    Scand J Infect Dis Suppl; 2003; 106():70-4. PubMed ID: 15000589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy.
    Ross L; Johnson M; Graham N; Shaefer M; St Clair M
    J Hum Virol; 1999; 2(5):290-5. PubMed ID: 10551735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
    Kuritzkes DR; Sevin A; Young B; Bakhtiari M; Wu H; St Clair M; Connick E; Landay A; Spritzler J; Kessler H; Lederman MM
    J Infect Dis; 2000 Feb; 181(2):491-7. PubMed ID: 10669331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiretroviral resistance mutations among pregnant human immunodeficiency virus type 1-infected women and their newborns in the United States: vertical transmission and clades.
    Palumbo P; Holland B; Dobbs T; Pau CP; Luo CC; Abrams EJ; Nesheim S; Vink P; Respess R; Bulterys M;
    J Infect Dis; 2001 Nov; 184(9):1120-6. PubMed ID: 11598834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant.
    Johnson VA; Petropoulos CJ; Woods CR; Hazelwood JD; Parkin NT; Hamilton CD; Fiscus SA
    J Infect Dis; 2001 Jun; 183(11):1688-93. PubMed ID: 11343221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of HIV-1 drug resistance in antiretroviral-naive pregnant Thai women.
    Auswinporn S; Jenwitheesuk E; Panburana P; Sirinavin S; Vibhagool A; Chantratita W
    Southeast Asian J Trop Med Public Health; 2002 Dec; 33(4):818-21. PubMed ID: 12757232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication.
    Naeger LK; Margot NA; Miller MD
    Antivir Ther; 2001 Jun; 6(2):115-26. PubMed ID: 11491416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New mutations associated with resistance not detected following zidovudine monotherapy in pregnancy when used in accordance with British HIV Association guidelines.
    Read P; Costelloe S; Mullen J; O'Shea S; Lyons F; Hay P; Welch J; Larbalestier N; Taylor G; de Ruiter A
    HIV Med; 2008 Aug; 9(7):448-51. PubMed ID: 18840150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in human immunodeficiency virus (HIV) counseling, testing, and antiretroviral treatment of HIV-infected women and perinatal transmission in North Carolina.
    Fiscus SA; Adimora AA; Schoenbach VJ; McKinney R; Lim W; Rupar D; Kenny J; Woods C; Wilfert C; Johnson VA
    J Infect Dis; 1999 Jul; 180(1):99-105. PubMed ID: 10353867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to antiretrovirals in HIV-infected pregnant women.
    Weinberg A; Forster-Harwood J; McFarland EJ; Pappas J; Davies JK; Kinzie K; Barr EA; Paul SM; Salbenblatt CR; Soda E; Vazquez A; Levin MJ
    J Clin Virol; 2009 May; 45(1):39-42. PubMed ID: 19329355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deletions in the beta3-beta4 hairpin loop of HIV-1 reverse transcriptase are observed in HIV-1 isolated from subjects during long-term antiretroviral therapy.
    Ross L; Johnson M; Ferris RG; Short SA; Boone LR; Melby TE; Lanier R; Shaefer M; St Clair M
    J Hum Virol; 2000; 3(3):144-9. PubMed ID: 10881994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect.
    Jeeninga RE; Keulen W; Boucher C; Sanders RW; Berkhout B
    Virology; 2001 May; 283(2):294-305. PubMed ID: 11336554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine.
    Paolucci S; Baldanti F; Campanini G; Cancio R; Belfiore A; Maga G; Gerna G
    Antiviral Res; 2007 Nov; 76(2):99-103. PubMed ID: 17640745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.
    Boyer PL; Imamichi T; Sarafianos SG; Arnold E; Hughes SH
    J Virol; 2004 Sep; 78(18):9987-97. PubMed ID: 15331732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fast genotypic detection of drug resistance mutations in the HIV-1 reverse transcriptase gene of treatment-naive patients.
    Fontaine E; Lambert C; Servais J; Ninove D; Plesséria JM; Staub T; Arendt V; Kirpach P; Robert I; Schneider F; Hemmer R; Schmit JC
    J Hum Virol; 1998; 1(7):451-6. PubMed ID: 10195266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug resistance among HIV-infected pregnant women receiving antiretrovirals for prophylaxis.
    Duran AS; Losso MH; Salomón H; Harris DR; Pampuro S; Soto-Ramirez LE; Duarte G; de Souza RS; Read JS;
    AIDS; 2007 Jan; 21(2):199-205. PubMed ID: 17197811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.